Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today reported financial results for second quarter 2017
and associated company developments.
Commercial Update
Second quarter 2017 product prescriptions for Trokendi XR® and
Oxtellar XR®, as reported by IMS, totaled 158,752, a 28.1% increase
over the second quarter of 2016.
|
Prescriptions |
|
|
Q2 2017 |
Q2 2016 |
Change % |
Trokendi XR |
124,229 |
93,223 |
33.3% |
|
Oxtellar XR |
34,523 |
30,726 |
12.4% |
|
Total |
158,752 |
123,949 |
28.1% |
|
Source: IMS
Net product sales for the second quarter of 2017 were $73.3
million, a 45.7% increase over $50.3 million in the same period the
prior year.
|
Net Product Sales ($mil.) |
|
|
Q2 2017 |
Q2 2016 |
Change % |
Trokendi XR |
$56.0 |
$37.6 |
48.9% |
|
Oxtellar XR |
$17.3 |
$12.7 |
36.2% |
|
Total |
$73.3 |
$50.3 |
45.7% |
|
|
|
|
|
|
Trokendi XR Migraine Launch
In April 2017, the Company launched Trokendi XR as a new
treatment for prophylaxis of migraine headache in adults and
adolescents 12 years and older. Since launch, IMS prescription data
for Trokendi XR has shown robust acceleration in prescription
growth.
For the second quarter of 2017, total prescriptions for Trokendi
XR increased by 22.2% from the first quarter of 2017. This compares
to an increase of 8.1% in the second quarter of 2016 over the first
quarter of 2016. Similarly, for the same sequential
quarter-to-quarter time periods, new prescriptions for Trokendi XR
increased by 31.2% in 2017, compared to 5.8% in 2016.
|
|
Prescription Growth Compared to
Q1 |
|
|
|
Q2 2017 |
|
Q2 2016 |
|
|
Prescriptions |
Change % |
|
Prescriptions |
Change % |
Trokendi XR - Total |
|
22,534 |
22.2% |
|
|
6,996 |
8.1% |
|
Trokendi XR - New |
|
14,594 |
31.2% |
|
|
2,352 |
5.8% |
|
Source: IMS
“We are very pleased with the launch of Trokendi XR in migraine
prophylaxis, which we believe is a reflection of the positive
feedback we have recently received from physicians because of the
clinical benefits Trokendi XR offers to patients,” said Jack
Khattar, President and CEO of Supernus Pharmaceuticals.
“As a result of the continued strong launch and the outstanding
performance of our sales organization, we plan to expand our
salesforce by approximately 40 sales representatives by the fourth
quarter of 2017. The expanded salesforce will consist of more than
200 sales representatives in total and will provide additional
support to both Trokendi XR and Oxtellar XR,” said Jack
Khattar.
Progress of Product Pipeline
Enrollment continues in both Phase III trials for SPN-810,
currently in development for Impulsive Aggression in patients aged
6 to 12 years who have ADHD. Enrollment into the Phase III trials
has shown steady progress as a result of the protocol revisions and
programs implemented to improve patient retention and drive patient
enrollment. Enrollment is at approximately 60% and 50% of target
patient enrollment in the first and second trials, respectively.
The Company expects enrollment to continue through mid-2018. The
Company is also discussing with the U.S. Food and Drug
Administration (FDA) expanding the program to include the
adolescent population.
Regarding SPN-812, the Company continues to plan to initiate
Phase III clinical testing during the second half of 2017 following
a meeting with the FDA in June 2017. The Company is finalizing its
protocols that include the pediatric and adolescent patient
populations.
The Oxtellar XR investigator-sponsored trial in bipolar disorder
is also on track to start in the third quarter of 2017.
Operating Expenses
Research and development expenses in the second quarter of 2017
were $10.8 million, as compared to $11.1 million in the same
quarter last year. This decrease is primarily due to the completion
of enrollment in 2016 of the Phase IIb trial for SPN-812.
Selling, general and administrative expenses in the second
quarter of 2017 were $35.1 million, as compared to $26.1 million in
the same quarter last year. The increase is primarily due to
promotional activities and programs related to the April 2017
launch of the migraine headache indication for Trokendi
XR.
Operating Income and Earnings Per Share
Operating income in the second quarter of 2017 was $26.1
million, a 123.8% increase over $11.6 million in the same period
the prior year. This improvement in operating income is primarily
due to increased net product sales, partially offset by increased
selling, general and administrative expenses.
Diluted earnings per share for the second quarter of 2017 were
$0.32 compared to $0.18 in the same period last year, an increase
of 77.8% over the prior year. Diluted earnings per share for the
second quarter of 2017 reflects an effective tax rate of 34.3%, as
compared to an effective tax rate of 3.8% during the second quarter
of 2016.
Weighted-average diluted common shares outstanding were
approximately 53.2 million in the second quarter of 2017, as
compared to approximately 51.7 million in the same period the prior
year.
Capital Resources
As of June 30, 2017, the Company had $197.6 million in cash,
cash equivalents, marketable securities, and long term marketable
securities, as compared to $165.5 million at December 31, 2016. As
of July 31, 2017, the Company had fully converted all of its
outstanding notes.
Financial Guidance
For full year 2017, the Company is raising its expectations for
both net product sales and operating income, and reiterating its
expectation for research and development expense as set forth
below:
- Net product sales in the range of $280 million to $290 million,
or $15 million higher than the previously expected range of $265
million to $275 million.
- Research and development expense of approximately $55
million.
- Operating income in the range of $82 million to $87 million, or
$7 million higher than the previously expected range of $75 million
to $80 million. The Company continues to expect that full year 2017
operating income will include approximately $5 million of non-cash
royalty revenue.
Conference Call Details
The Company will hold a conference call hosted by Jack Khattar,
President and Chief Executive Officer, and Greg Patrick, Vice
President and Chief Financial Officer, to discuss these results at
9:00 a.m. ET, on Thursday, August 3, 2017. An accompanying webcast
also will be provided.
Please refer to the information below for conference call
dial-in information and webcast registration. Callers should dial
in approximately 10 minutes prior to the start of the call.
Conference
dial-in: |
|
(877) 288-1043 |
International
dial-in: |
|
(970) 315-0267 |
Conference ID: |
|
55235874 |
Conference Call Name: |
|
Supernus
Pharmaceuticals Second Quarter 2017 Earnings Conference Call |
|
|
|
Following the live call, a replay will be available on the
Company's website, www.supernus.com, under ‘Investors’.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company currently
markets Trokendi XR® (extended-release topiramate) for the
prophylaxis of migraine and the treatment of epilepsy, and Oxtellar
XR® (extended-release oxcarbazepine) for the treatment of epilepsy.
The Company is also developing several product candidates to
address large market opportunities in psychiatry, including SPN-810
for the treatment of Impulsive Aggression in ADHD patients and
SPN-812 for the treatment of ADHD.
Forward-Looking Statements:
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements do not convey historical information, but
relate to predicted or potential future events that are based upon
management's current expectations. These statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. In
addition to the factors mentioned in this press release, such risks
and uncertainties include, but are not limited to, the Company’s
ability to sustain and increase its profitability; the Company’s
ability to raise sufficient capital to fully implement its
corporate strategy; the implementation of the Company’s corporate
strategy; the Company’s future financial performance and projected
expenditures; the Company’s ability to increase the number of
prescriptions written for each of its products; the Company’s
ability to increase its net revenue; the Company’s ability to enter
into future collaborations with pharmaceutical companies and
academic institutions or to obtain funding from government
agencies; the Company’s product research and development
activities, including the timing and progress of the Company’s
clinical trials, and projected expenditures; the Company’s ability
to receive, and the timing of any receipt of, regulatory approvals
to develop and commercialize the Company’s product candidates; the
Company’s ability to protect its intellectual property and operate
its business without infringing upon the intellectual property
rights of others; the Company’s expectations regarding federal,
state and foreign regulatory requirements; the therapeutic
benefits, effectiveness and safety of the Company’s product
candidates; the accuracy of the Company’s estimates of the size and
characteristics of the markets that may be addressed by its product
candidates; the Company’s ability to increase its manufacturing
capabilities for its products and product candidates; the Company’s
projected markets and growth in markets; the Company’s product
formulations and patient needs and potential funding sources; the
Company’s staffing needs; and other risk factors set forth from
time to time in the Company’s SEC filings made pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934, as amended. The
Company undertakes no obligation to update the information in this
press release to reflect events or circumstances after the date
hereof or to reflect the occurrence of anticipated or unanticipated
events.
|
Supernus Pharmaceuticals, Inc. |
Consolidated Balance Sheets |
(in thousands) |
|
|
|
|
|
|
|
|
|
|
June 30, 2017 |
|
December 31, 2016 |
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents
and marketable securities |
|
$ |
92,966 |
|
|
$ |
90,121 |
Accounts receivable,
net |
|
|
51,157 |
|
|
|
41,527 |
Inventories, net |
|
|
16,623 |
|
|
|
16,801 |
Prepaid expenses and
other current assets |
|
|
4,746 |
|
|
|
2,955 |
Total current
assets |
|
|
165,492 |
|
|
|
151,404 |
|
|
|
|
|
|
|
|
Long term marketable
securities |
|
|
104,632 |
|
|
|
75,410 |
Property and equipment,
net |
|
|
4,572 |
|
|
|
4,344 |
Deferred legal
fees |
|
|
11,887 |
|
|
|
19,860 |
Intangible assets,
net |
|
|
28,989 |
|
|
|
16,490 |
Other non-current
assets |
|
|
349 |
|
|
|
331 |
Deferred income
tax |
|
|
30,449 |
|
|
|
41,729 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
346,370 |
|
|
$ |
309,568 |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
7,577 |
|
|
$ |
8,055 |
Accrued sales
deductions |
|
|
47,621 |
|
|
|
41,943 |
Accrued expenses |
|
|
23,434 |
|
|
|
27,427 |
Accrued income taxes
payable |
|
|
1,608 |
|
|
|
7 |
Non-recourse liability
related to sale of future royalties, current portion |
|
|
4,997 |
|
|
|
3,101 |
Deferred licensing
revenue |
|
|
287 |
|
|
|
209 |
Total current
liabilities |
|
|
85,524 |
|
|
|
80,742 |
|
|
|
|
|
|
|
|
Deferred licensing
revenue, net of current portion |
|
|
1,293 |
|
|
|
1,501 |
Convertible notes,
net |
|
|
1,472 |
|
|
|
4,165 |
Non-recourse liability
related to sale of future royalties, long term |
|
|
24,184 |
|
|
|
27,289 |
Other non-current
liabilities |
|
|
4,500 |
|
|
|
4,002 |
Derivative
liabilities |
|
|
- |
|
|
|
114 |
Total liabilities |
|
|
116,973 |
|
|
|
117,813 |
|
|
|
|
|
|
|
|
Total stockholders'
equity |
|
|
229,397 |
|
|
|
191,755 |
|
|
|
|
|
|
|
|
Total liabilities and
stockholders' equity |
|
$ |
346,370 |
|
|
$ |
309,568 |
|
|
|
|
|
|
|
|
Supernus Pharmaceuticals, Inc. |
Consolidated Statements of
Operations |
(in thousands, except share and per share
data) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months ended June 30, |
|
Six Months ended June 30, |
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
(unaudited) |
Revenue |
|
|
|
|
|
|
|
|
|
|
|
Net
product sales |
$ |
73,328 |
|
|
$ |
50,335 |
|
|
$ |
129,697 |
|
|
$ |
93,360 |
|
Royalty
revenue |
|
1,179 |
|
|
|
1,205 |
|
|
|
2,328 |
|
|
|
2,324 |
|
Licensing
revenue |
|
1,322 |
|
|
|
86 |
|
|
|
1,380 |
|
|
|
135 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
75,829 |
|
|
|
51,626 |
|
|
|
133,405 |
|
|
|
95,819 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
Cost of
product sales |
|
3,861 |
|
|
|
2,751 |
|
|
|
6,809 |
|
|
|
4,786 |
|
Research
and development |
|
10,823 |
|
|
|
11,109 |
|
|
|
20,425 |
|
|
|
21,671 |
|
Selling,
general and administrative |
|
35,078 |
|
|
|
26,121 |
|
|
|
63,316 |
|
|
|
51,281 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and
expenses |
|
49,762 |
|
|
|
39,981 |
|
|
|
90,550 |
|
|
|
77,738 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
26,067 |
|
|
|
11,645 |
|
|
|
42,855 |
|
|
|
18,081 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
(expense) |
|
|
|
|
|
|
|
|
|
|
|
Interest
income |
|
656 |
|
|
|
365 |
|
|
|
1,187 |
|
|
|
693 |
|
Interest
expense |
|
(58 |
) |
|
|
(196 |
) |
|
|
(147 |
) |
|
|
(375 |
) |
Interest
expense-nonrecourse liability related to sale of future
royalties |
|
(160 |
) |
|
|
(1,281 |
) |
|
|
(1,119 |
) |
|
|
(2,560 |
) |
Changes
in fair value of derivative liabilities |
|
23 |
|
|
|
123 |
|
|
|
76 |
|
|
|
224 |
|
Loss on
extinguishment of debt |
|
(103 |
) |
|
|
- |
|
|
|
(204 |
) |
|
|
(382 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Total other income
(expense) |
|
358 |
|
|
|
(989 |
) |
|
|
(207 |
) |
|
|
(2,400 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income
taxes |
|
26,425 |
|
|
|
10,656 |
|
|
|
42,648 |
|
|
|
15,681 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
tax expense |
|
9,057 |
|
|
|
405 |
|
|
|
14,983 |
|
|
|
605 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
$ |
17,368 |
|
|
$ |
10,251 |
|
|
$ |
27,665 |
|
|
$ |
15,076 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per common
share: |
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ |
0.34 |
|
|
$ |
0.21 |
|
|
$ |
0.55 |
|
|
$ |
0.31 |
|
Diluted |
$ |
0.32 |
|
|
$ |
0.18 |
|
|
$ |
0.52 |
|
|
$ |
0.28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average number
of common shares: |
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
50,530,968 |
|
|
|
49,427,825 |
|
|
|
50,345,830 |
|
|
|
49,333,962 |
|
Diluted |
|
53,223,714 |
|
|
|
51,745,342 |
|
|
|
53,026,323 |
|
|
|
51,484,686 |
|
|
|
|
|
|
|
|
|
|
|
|
|
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024